Lewy body dementia is a disease linked to abnormal deposits of a protein called alpha-synuclein in the brain.
These deposits, called Lewy bodies, affect chemicals in the brain whose changes, in turn, can lead to problems with thinking, movement, behavior, and mood.
Lewy body dementia is one of the most common causes of dementia.
There are no approved treatments for Lewy body dementia, the second most common cause of neurodegenerative dementia.
And there is an urgent need to find therapies for this and related disorders such as Alzheimer’s disease.
In a recent study at the University of North Carolina at Chapel Hill, scientists found that people with mild-to-moderate Lewy body dementia had a big improvement in cognition when they took the drug neflamapimod three times daily.
The finding from the trial of neflamapimod in dementia with Lewy bodies is very encouraging.
The team is expected to be included as a study site for the planned phase 3 clinical trial.
They say the exciting results of the phase 2 study showing the benefit of the new drug neflamapimod for cognition in dementia with Lewy bodies will bring hope to patients and their caregivers.
If these findings are confirmed in a phase 3 study, the potential impact on patients with dementia with Lewy bodies will be significant.
If you care about dementia, please read studies about how the Mediterranean diet could protect your brain health, and Vitamin B supplements could help reduce dementia risk.
For more information on brain health, please see recent studies about antioxidants that could help reduce dementia risk, and how Alzheimer’s attacks the brain.
The study was conducted by Jeffrey L. Cummings et al.
Copyright © 2022 Knowridge Science Report. All rights reserved.
